0%
中文
中文
Home > About us > Company
AlphaNa is an innovation-driven bioscience company focused on addressing critical unmet medical needs by translating original RNA research into high-quality therapeutics with clinical value. Built upon our proprietary TALENT® platform, we have established a R&D portfolio across three core areas including in vivo cell engineering, next-generation nucleic acid therapeutics, and innovative vaccines, with multiple pipelines advancing into pivotal clinical stages. AlphaNa has led and participated in 7 national-level key research programs as well as multiple provincial and ministerial initiatives, and is continuously strengthening an intellectual property portfolio comprising nearly 100 patents and patent applications. We are building an integrated research and industrialization ecosystem spanning drug discovery, clinical translation, and bio-manufacturing.
Achievements & Awards
2026 2025 2024 2023 2022 2021
2026

Start of a Phase 2 clinical trial for therapeutic HPV mRNA vaccine and herpes zoster mRNA vaccine

2025

Publication in Nature Biomedical Engineering (Our Innovative Breakthrough: Generating Tolerogenic Antigen-Presenting Cells in Vivo)

Completion of Pre-A3 round financing

Start of Phase 2 clinical trial for RSV mRNA vaccine

First human dose of Herpes zoster mRNA vaccine

First human dose of an individualized neoantigen-based mRNA vaccine for metastatic/ R/R solid tumor

7 National Key R&D Programs Secured to date, funded by the Ministry of Science and Technology (MOST), National Natural Science Foundation of China (NSFC) and the National Health Commission (NHC)

2024

Completion of Pre-A2 round financing

Established a subsidiary in Shanghai

First human dose of RSV mRNA vaccine

First human dose of Therapeutic HPV mRNA vaccine for cervical High-grade Squamous Intraepithelial Lesion (HSIL)

Publication in Molecular Therapy

4 National Key R&D Programs secured under the direct sponsorship of the National Laboratory and the Ministry of Science and Technology (MOST)

2023

Completion of Pre-A1 round financing

Received clinical trial approval for a COVID-19 mRNA vaccine targeting the Omicron variant

Funded by National Key R&D Programs led by the Ministry of Science and Technology of China

Publication in Cell research

Recognized as National High-Tech Enterprise

2022

Establishment of a comprehensive platform (TALENT®) to enable design, proof of concept and preclinical validation, scalable manufacturing of mRNA-based medicines

Established a new company with Anhui Anke Biotechnology (Group) Co., Ltd.

2021

Founded in the district of Economic and Technological development, Hefei, Anhui

Completion of Angel round financing

Pipeline
Partnership
Investor